A Phase II Trial of Celecoxib Plus Interferon Alpha in Metastatic Renal Cell Carcinoma Patients With 3+ COX-2 Tumor Immunostaining.
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2012
At a glance
- Drugs Celecoxib (Primary) ; Interferon alpha-2b (Primary)
- Indications Renal cell carcinoma
- Focus Biomarker; Therapeutic Use
- 25 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Apr 2011 Actual end date (Oct 2010) added as reported by ClinicalTrials.gov.
- 12 Jan 2011 Planned End Date changed from 1 Dec 2010 to 1 Dec 2011as reported by ClinicalTrials.gov.